皮肤癌诊断服务商Castle Biosciences, Inc. (CSTL) 2024年第三季度财报喜人,股价在周四盘中大涨6.54%,引发市场关注。
数据显示,Castle Biosciences本季度营收达8,578万美元,同比劲增39.5%,超出分析师预期。调整后每股实现盈利0.08美元,相比去年同期亏损0.26美元有了大幅改善,也大大超出分析师预期的0.06美元亏损。
这一亮眼的业绩表现反映出该公司在皮肤癌诊断领域拥有良好发展势头,加之其强劲增长前景,赢得了投资者青睐。分析师认为,该公司销售渠道和产品线持续扩张有望继续推动业绩增长,对其长期前景持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.